DR G.H. GERDES & REF. LABORATORY STAFF ONDERSTEPOORT

Similar documents
Lumpy skin disease and bluetongue training of trainers in FYR of Macedonia Skopje, September 2017

Vaccination against Bluetongue

INTERNATIONAL WORKSHOP BLUETONGUE VACCINES 19 February 2013, Strasbourg, France ABSTRACTS

transmitted by midges (Culicoides spp.) world-wide prevalence unknown to central Europe until 2006 Serotype 8

ZOETIS ARE PROUD TO SUPPORT THE JOINT ACTION AGAINST BLUETONGUE CAMPAIGN

Meeting of the Ministers o Agriculture and Food From South Eastern Europe in relation to Bluetongue disease

Update on the BTV situation in France. Pascal HUDELET, LA & VPH Customer Service Sept 2015

RIFT VALLEY FEVER AN EVALUATION OF THE OUTBREAKS IN SOUTH AFRICA

NFU INFORMATION & ANALYSIS

WHAT CAN BE LEARNED FROM VETERINARY VACCINES; THE DIVA CONCEPT

The emergence, persistence and evolution of bluetongue viruses in Europe since 1998 Peter Mertens. School of Veterinary Medicine and Science

The use of vaccination in the control of bluetongue in southern Africa

THE CYTOPATHOGENIC ACTION OF BLUETONGUE VIRUS ON TISSUE CULTURES AND ITS APPLICATION TO THE DETECTION OF ANTIBODIES IN THE SERUM OF SHEEP.

Foot and Mouth Disease Middle East situation Summary of Answers to the Questionnaire Beirut, Lebanon, 7 9 April 2009

BIOLOGY OF RVF THE DISEASE

Foot-and-mouth disease. Andrew McFadden MVS, BVSc Veterinary Epidemiologist

Rift Valley Fever: Preventing epizootics and epidemics by livestock vaccination

A PRELIMINARY ANTIGENIC CLASSIFICATION OF STRAINS OF BLUETONGUE VIRUS

Elements of the FMD control problem in Southern Africa: 2

Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. 2004, 8203 AA Lelystad, The Netherlands * Corresponding Author

Rift Valley Fever in Africa. Kariuki Njenga, DVM, PhD Centers for Disease Control & Prevention, Nairobi, Kenya

Akabane Virus Risk Management in Australia. P.D. Kirkland, EMAI, Camden NSW Australia.

BLUETONGUE: PATHOGENESIS AND DURATION OF VIREMIA N James MacLachlan

LSD epidemiology and diagnosis (clinical & laboratory)

Rift valley fever: Next generation vaccines for an old foe

landbouw, natuur en voedselkwaliteit Epidemiological report BTV 6 in the Netherlands

Rift Valley Fever. What is Rift Valley Fever?

Better Training for Safer Food BTSF

Foot and mouth disease situation and control strategies in the People s Republic of China the current situation

"Schmallenberg" virus: likely epidemiological scenarios and data collection

1 Federal Agency for the Security of the Food Chain. BLUETONGUE Belgium. Situation in ruminants SCOFCAH, Brussels, August, 28 th 2006

Rift Valley Fever. Strategy for RVF vaccination. Dr Victor Mbao Mombasa, Kenya November 2012

Climate changes and animal infectious diseases

Overview on Lumpy skin disease in the Mediterranean region: From Middle East to Europe

Rift Valley Fever Virus: Diagnosis and Vaccines. M. Kariuki Njenga, BVM, PhD Centers for Disease Control and Prevention Nairobi, Kenya

Scientific discussion

EPIDEMIOLOGICAL SITUATION. for S&GP, PPR andbt

Bluetongue: brief overview of the disease. Bluetongue in sheep

Foot and Mouth Disease

FMD in Libya. Dr. Abdunaser Dayhum National Center of Animal Health Libya

Better Training for Safer Food BTSF

Scientific Opinion on sheep pox and goat pox - first part

Estimations of the Infective Period for Bluetongue in Cattle

Animal Disease Reporting for the month August 2017

Animal Disease Surveillance in South Africa. Submitted by South Africa

Regulation of FMD vaccines within the European Union

OUTLINE INTRODUCTION 10/17/2011. Introduction Current Knowledge Future Directions

Are Dromedary Camels Susceptible or Non-Susceptible to Foot-and-Mouth Disease Serotype O

African Horse Sickness (AHS) and Equine Encephalosis (EE) in The Gambia

BLUETONGUE CONTROL STRATEGY, INCLUDING RECOURSE TO VACCINE

INITIAL EPIDEMIOLOGICAL REPORT ON THE OUTBREAK OF BLUETONGUE IN EAST ANGLIA AND SOUTH EAST ENGLAND FROM INVESTIGATIONS COMPLETED TO 19 OCTOBER 2007

FMD Carrier state and role of carrier buffalo as source of transboundary spread in Southeast Asia and Eastern Asia Satya Parida

Risk Assessment Centre on Food Chain Project link to the Delphi priorities / EFSA Strategy topics

Situtation of France regarding BTV 8. 8th october 2015 A. Fediaevsky, MAAAF/DGAL/SDSPA/BSA

Exotic diseases approaching EU EFSA mandates on PPR, sheep pox, lumpy skin disease

EDQM Workshop. Bluetongue Vaccines

BLUETONGUE IN ITALY: RISK ANALYSIS ON THE INTRODUCTION INTO FREE TERRITORIES OF VAC- CINATED ANIMALS FROM RE- STRICTED ZONES.

Bluetongue in Italy: Part II

RISK FACTORS, INCIDENCE AND PREVALENCE OF BLUETONGUE IN ROMANIA AND WORLDWIDE IN THE LAST DECADE

Rift Valley Fever RVF. Enhancing Safe Inter-Regional Livestock Trade Dubai, United Arab Emirates June 13-16, 2011

Dr Ghazi Yehia OIE Regional Representative for the Middle East

Revision of the RVF chapter in the OIE Terrestrial Manuel D.Goovaerts, IFAH. Mombasa, November 14 th 2012

Emerging Infections: Pandemic Influenza. W. Paul Glezen

This CRP is proposed for five years with three RCM. To apply, please see our website for directions:

Toward the control of Foot-and-Mouth disease in East Asia

Genetically engineered structure-based vaccine for bluetongue disease

Foot and mouth disease control strategies in North Africa and the Middle East the current

Standing Group of Experts on LSD in South-East Europe

Today s Presentation. Bluetongue and related Orbiviruses a global update

Portuguese Experience on Bluetongue Vaccination

Exotic diseases approaching EU EFSA mandates on Peste des Petits Ruminants (PPR) and lumpy skin disease (LSD) coordinated by Alessandro Broglia

Scientific discussion

Bluetongue in the Federal Republic of Germany. final report. SCOFCAH, Brussels, January 2012

Excretion of bluetongue virus in cattle semen: a feature of laboratory-adapted virus

Foot and Mouth Disease Control, A vaccine perspective. John Barlow, DVM PhD

Studies of the Antigenic relationships between Bluetongue virus serotypes 2, 9 & 15 isolated in Andhra Pradesh, India

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

in control group 7, , , ,

RIFT VALLEY FEVER : A DISEASE UPDATE. Dr Pamela Oberem BVSc (Hons) P.O. Box Onderstepoort

Foot and Mouth Disease Vaccine Research and Development in India

Global situation Vet. Ital., 40 (3), Japan

Importance of Vaccines for Managing FMD

Federal Department of Home Affairs FDHA. Federal Food Safety and Veterinary Office FSVO Animal Health

Distribution of bluetongue in the United States of America,

Update to Iowa Foot and Mouth Disease (FMD) and Livestock Emergency Management Plans

Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص

Why to vaccinate? Lumpy skin disease prevention, control, and awareness workshop Budapest, Hungary, 7-9 March 2017

The history of bluetongue and a current global overview

LUMPY SKIN DISEASE. Exotic diseases approaching EU: Alessandro Broglia Animal and Plant Health Unit European Food Safety Authority - EFSA

The Royal Veterinary College. The Swiss Federal Veterinary Office


ASEAN STANDARDS FOR ANIMAL VACCINES

Regional Status and FMD s Control Strategies in North Africa

Introduction. Transmission

Report on the Foot and Mouth Disease outbreak in KwaZulu Natal. 20 May 2011

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Lisbon, Portugal, 20 September The Russian Federation LSD report Dr Artem Metlin

Recombinant Virus Vaccine for Bluetongue Disease in Sheep

Overview of WRL FMD. Historical perspective. Principal activities. FMD threats. Needs/prospects. David Paton

Vaccination against bluetongue in Spain

Transcription:

DR G.H. GERDES & REF. LABORATORY STAFF ONDERSTEPOORT

SOUTH AFRICA < Sub tropical N. East > 30th driest country Total Ruminants 12 mill. cattle Temperate S West 5 mill. goats 28 mill. sheep

THE VIRUS -background Entire southern Africa endemic (Sahara) - present since antiquity - introduction merino sheep late 18th C - 1943 C.imicola vector - 1948 plurality of serotypes pre 1960-12 serotypes 1960-1970 - 4 serotypes post 1970-8 serotypes

(cont.) - two large merino introductions late 1600 and late 1700 - BT recognized in early 1800-1876 outbreak serious febrile disease - SNTs developed typing (first 12 then 16 serotypes) - Theiler 1900 Cape Province BTV 4 oldest

BTV SEROTYPES 1983-2003 60 I s o l a t e s 50 40 30 20 10 Sheep Isolates - 258 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 BT Serotypes *

1983-2003 HIGH EPIDEMIC POTENTIAL C a s e s C a s e s 50 45 40 35 30 25 20 15 10 5 0 50 45 40 35 30 25 20 15 10 5 0 1 2 3 4 5 6 8 11 24 Serotypes LOW EPIDEMIC POTENTIAL 7 15 18 C a s e s 50 45 40 35 30 25 20 15 10 5 0 EVERY SEASON LOWER LEVELS 9 10 12 13 16 19 Serotypes Serotypes

CULICOIDES SURVEY 1978-1985 I s o l a t e s 25 20 15 10 5 Onderstepoort : not the highest or lowest hottest wettest but > no. of collections > no. of isolates > no. of serotypes 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 BT Serotypes *

BLUETONGUE IN CATTLE Up to the present (1932) it has been accepted that bluetongue is a disease specifically and exclusively confined to sheep (Bekker et al 1934)

BLUETONGUE TRIAL SYMPTOMS FIELD CATTLE EXPERIMENTAL CATTLE EXPERIMENTAL SHEEP Eye discharge + + + Nose discharge + + + Salivation ++ slight Frothing Swollen tongue + - + Stomatitis ++ + ++ Torticollis - - + (late) Skin lesions + - + Stiffness + - - S/c oedema - - + Coronitis + - ++ (Bekker et al 1934)

DISEASE IN CATTLE 1996 C a s e s 10 9 8 7 6 5 4 3 2 1 0 BTV 12, 15, 22 cattle strains Closely related to EHD 1 2 3 4 5 6 7 8 Serotypes Ovine Bovine

BLUETONGUE IN GAME Dec. < role as maintenance/amplifying host (23 official protected areas) 500 450 A - Export data B - Survey data A: In 4 yrs exported - 1,511 game 30% BT Pos. N u m b e r 400 350 300 250 200 150 100 50 0 1997 1998 1999 2000 Total Positive

% P o s i t i v e 100 90 80 70 60 50 40 30 20 10 0 B: Single survey 1997-4 vegetation types - rainfall 280mm. 900mm 1 2 3 4 5 6 7 8 9 10 11 12 Game (Barnard 1997) BT 1. Blk w/beest 2. Bl w/beest 3. Red h/beest 4. Bl/buck 5. S/buck 6. Impala 7. G/buck 8. Buffalo 9. Kudu 10. Eland 11. B/buck 12. Giraffe

VACCINE - background 1 - Theiler Sheep blood vaccine BTV 4 - used at # 11, 33, 54 alternative host system egg - progressive serial # in eggs (temp) 2 - pre 1959 used polyvalent egg attenuated (BTV 3, 4, 11, 12)

ATTENUATION - Absence of clinical Sx? Attenuation - Index of infection = solid homologous immunity after challenge - attenuation - decrease severity fever - absence mouth and foot lesions - shortened febrile reaction

(cont.) BTV 9 & 10 most pronounced clinical Sx prolonged viraemia Higher egg # foot lesions disappeared Low virus yield in some egg strains go to TC Pathogenicity of original virus reduced by serial # Febrile reaction ± 1 day Egg/TC better than Egg only

No concept Master Seed Virus Some egg # >100 3 14 strains (TC adapted Egg attenuated) in 1 dose failed to stimulate polyvalent immunity - loss antigenicity - role interferon - competition between 2 Ag s - rapid : slower growing strains Viraemia essential for high a/b titers (cont.)

EVOLUTION OF A NEW VACCINE Effective & Practical control measure Goals : Inactivated - complete inactivation - minimal loss antigenicity Attenuated - adaptation to new host or prolonged # in TC - genetically stable agent - avirulent

(cont.) Move away - highly attenuated egg# Selection of strains - use of 14 strains in 1 1 14 were not selected used (old and widespread) (3) 17, 20, 21 exotic (6) 15, 16, 18, 22, 23, 24 low pathogenicity for sheep low presence in Culicoides all recent isolates

(cont.) 1976 floods outbreak of two new viruses BTV 18 & 19 19 very pathogenic Directly related to 7 (weak immunogen) 19 became the 15 strain of the 3 x pentavalent product A B- C divide based on degree attenuation degree relatedness BTV 4 A (amnestic response) 10 11 B 13 C

BTV VP2 11 17 12 22 19 4 24 23 7 20 9 1 2 15 18 8 14 10 21 6 3 13 5 16 3 16 13 14 6 21 23 8 18 1 2 5 9 7 19 10 4 20 24 11 17 15 12 22 0.2 Serological relationship Phylogenetic relationship

VACCINE STRAINS HAD HAVE 1 53 E 4TC 50 E 3P 4BHK 2 80 E 50 E 3P 4BHK 3 60 E 45 E 2 BHK 3P 5BHK 4 80 E 60 E 3P 9BHK 5 63 E 50 E 2BHK 3P 6BHK 6 80 E 60E 3P 7BHK 7 80 E 60 E 3P 4BHK 8 80 E 50 E 3BHK 10P 7BHK 9 80 E 70 E ---- 10 80 E E 82 11 45 E 35 E 3P 5BHK 12 60 E 55 E 3P 4BHK 13 80 E 45 E 2BHK 3P 4BHK 14 80 E 60 E 3P 4BHK 19 29 E 3P 3BHK

BTV VACCINE STRAINS Not all South African exotics in vaccine 3 - Cyprus 10 - Portugal 16 - Pakistan East : West Italians have BTV 9 E Vaccine is BTV 9 W Effective (a/body)

(cont.) Primary vacc. Bottle A a/bodies to 3 - Bottles A, B, C protection against 9 Annual vacc. X 3 full protection to 15 - chose the lowest available egg passage - plaque purify on TC Modified live - plaque selection avirulent/virulent ratio (no genetic marker choose large number)

(cont.) chose 10 P 3 P 1 P sheep sheep sheep vaccine candidate Extensively tested - SA conditions - SA merinos In use 40 yrs 12 14 million doses 8 million doses

CAUTION - Live attenuated risks * not first ½ pregnancy * temporary infertility - Objections * reversion to virulence * re assortment * vector spread (viraemia) * no DIVA test trade difficulties Teratogenicity - potent cause of early foetal death - lesser extent foetal malformations

RE ASSORTMENT EU PROJECT VP2 sequences 130 strains 1982 2003-8 vaccine strains BTV 2, 3, 5, 6, + 14 1982 death - PAGE gel 7 vaccine segments + - animal trial pending

MISCELLANEOUS 1. Game - springbok with mouth lesions/muscle necrosis - sable antelope with torticollis 2. Alpacca - two separate submissions with pneumonia 3. Goats - often with coronitis - Angoras with hyperaemia base horns - drop in milk production & torticollis (Saanen) Abortion?

FOOT NOTE A Vaccination History:- 1. Unvaccinated 24 cases 13 serotypes 2. Vaccinated 16 cases 6 serotypes - multiple serotypes - majority were BTV 4, 3 and 12 - only BTV 16 and 24 not in the vaccine

FOOT NOTE B Serotype 16 - not South Africa - not in the vaccine -Eastern strain - included in an Israeli product -recent strain - not tested in the field here